Cross-resistance to cladribine (CdA) and cytarabine (Ara-C) in human etoposide-resistant cell lines

被引：0
|
作者：
Albertioni, F [1 ]
Lotfi, K [1 ]
Wang, Y [1 ]
Xu, D [1 ]
Knaust, E [1 ]
Lillemark, E [1 ]
Eriksson, S [1 ]
机构：
[1] Karolinska Hosp, Dept Clin Pharmacol, S-17176 Stockholm, Sweden
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
562
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [41] Expression signature of therapy resistant AML: Use of in vitro selected ara-C resistant BXH-2 strain AML cell lines.
    Tsai, ML
    Yin, B
    Hasz, DE
    Largaespada, DA
    BLOOD, 2004, 104 (11) : 560A - 561A
  • [42] Molecular and biochemical analysis of multidrug resistant human promyelocytic cell line (HL60) showing cross-resistance to cytarabine:: Synergic effects of cytarabine with sandimmun (CSA) and valspodar (PSC833).
    Albertioni, F
    Månsson, E
    Ullberg, K
    Paul, A
    Eriksson, S
    Paul, C
    BLOOD, 2000, 96 (11) : 178B - 178B
  • [43] In vivo etoposide-resistant C6 glioma cell line: Significance of altered DNA topoisomerase II activity in multi-drug resistance
    Takuyu Taki
    Takanori Ohnishi
    Norio Arita
    Shoju Hiraga
    Toru Hayakawa
    Journal of Neuro-Oncology, 1998, 36 : 41 - 53
  • [44] Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines
    Johnson, SW
    Shen, DW
    Pastan, I
    Gottesman, MM
    Hamilton, TC
    EXPERIMENTAL CELL RESEARCH, 1996, 226 (01) : 133 - 139
  • [45] ANTITUMOR ACTIVITY OF NOVEL HETERODINUCLEOSIDE PHOSPHATES CONSISTING OF 5-FLUORODEOXYURIDINE AND ARA-C IN SELECTED HUMAN CANCER CELL LINES
    Saiko, Philipp
    Horvath, Zsuzsanna
    Bauer, Wolfgang
    Hoechtl, Thomas
    Illmer, Christoph
    Madlener, Sibylle
    Grusch, Michael
    Krupitza, Georg
    Mader, Robert
    Schott, Herbert
    Fritzer-Szekeres, Monika
    Szekeres, Thomas
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3645 - 3646
  • [46] Cytotoxic and apoptotic effects of novel heterodinucleoside phosphates consisting of 5-fluorodeoxyuridine and ara-c in human cancer cell lines
    Saiko, P
    Bauer, W
    Horvath, Z
    Hoechtl, T
    Grusch, M
    Illmner, C
    Madlener, S
    Krupitza, G
    Mader, RM
    Schott, H
    Fritzer-Szekeres, M
    Szekeres, T
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9): : 1507 - 1511
  • [47] Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein
    Fu, CH
    Martin-Aragon, S
    Weinberg, KI
    Ardi, VC
    Danenberg, PV
    Avramis, VI
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (02) : 123 - 133
  • [48] Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein
    Cecilia H. Fu
    Sagrario Martin-Aragon
    Kenneth I. Weinberg
    Veronica C. Ardi
    Peter V. Danenberg
    Vassilios I. Avramis
    Cancer Chemotherapy and Pharmacology, 2001, 48 : 123 - 133
  • [49] In vivo etoposide-resistant C6 glioma cell line:: Significance of altered DNA topoisomerase II activity in multi-drug resistance
    Taki, T
    Ohnishi, T
    Arita, N
    Hiraga, S
    Hayakawa, T
    JOURNAL OF NEURO-ONCOLOGY, 1998, 36 (01) : 41 - 53
  • [50] LEAM protocol (Lomustine, Etoposide, Ara-C/Cytarabine, Melphalan) as high-dose chemotherapy (HDT) before autologous stem cell transplant (ASCT) for lymphoid malignancies: a monocentric experience
    Fornecker, L. M.
    Ledoux, M. P.
    Toussaint, E.
    Laplace, A.
    El Aatmani, A.
    Fohrer-Sonntag, C.
    Bilger, K.
    Lioure, B.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S238 - S239
12345